Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
- PMID: 32198163
- PMCID: PMC7157814
- DOI: 10.1128/mBio.00398-20
Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
Abstract
Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.
Keywords: COVID-19; endothelial dysfunction; generic drugs; host response treatment.
Copyright © 2020 Fedson et al.
References
-
- The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. 2020. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly; 2:113–122. http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a.... Accessed 18 February 2020. - PMC - PubMed
-
- Shyamsundar M, McKeown STW, O'Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF. 2009. Simvastatin decreases lipopoly-saccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 179:1107–1114. doi:10.1164/rccm.200810-1584OC. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical